| Autor: |
Deusdará TT; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil., Félix MKC; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil., de S Brito H; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil., Cangussu EWS; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil., de S Moura W; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil., Albuquerque B; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil., Silva MG; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil., Dos Santos GR; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil.; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil., de Morais PB; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil., da Silva EF; Instituto Leônidas e Maria Deane, Oswaldo Cruz Foundation-Fiocruz Amazônia, Manaus 69057-070, AM, Brazil., Chaves YO; Instituto Leônidas e Maria Deane, Oswaldo Cruz Foundation-Fiocruz Amazônia, Manaus 69057-070, AM, Brazil., Mariúba LAM; Instituto Leônidas e Maria Deane, Oswaldo Cruz Foundation-Fiocruz Amazônia, Manaus 69057-070, AM, Brazil., Nogueira PA; Instituto Leônidas e Maria Deane, Oswaldo Cruz Foundation-Fiocruz Amazônia, Manaus 69057-070, AM, Brazil., Astolfi-Filho S; Laboratory of DNA Technology, Biotechnology Department, Multidisciplinary Support Center, Federal University of Amazonas, Manaus 69080-900, AM, Brazil., Assunção EN; Laboratory of DNA Technology, Biotechnology Department, Multidisciplinary Support Center, Federal University of Amazonas, Manaus 69080-900, AM, Brazil., Epiphanio S; Department of Immunology, Biomedical Science Institute, University of São Paulo (USP), São Paulo 05508-060, SP, Brazil., Marinho CRF; Department of Immunology, Biomedical Science Institute, University of São Paulo (USP), São Paulo 05508-060, SP, Brazil., Brandi IV; Institute of Agricultural Sciences, Federal University of Minas Gerais, Montes Claros 39400-310, MG, Brazil.; Department of Biotchnology, State University of Montes Claros, Montes Claros 39401-089, MG, Brazil., Viana KF; Interdisciplinary Center for Life Sciences and Nature, Federal University of Latin American Integration (UNILA), Foz do Iguaçu 85866-000, PR, Brazil., Oliveira EE; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil.; Departamento de Entomologia, Universidade Federal de Viçosa, Viçosa 36570-900, MG, Brazil., Cangussu ASR; Graduate Program for Biodiversity and Biotechnology of Legal Amazon, Federal University of Tocantins, Palmas 77001-090, TO, Brazil.; Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil. |
| Abstrakt: |
Acinetobacter baumannii is a Gram-negative, immobile, aerobic nosocomial opportunistic coccobacillus that causes pneumonia, septicemia, and urinary tract infections in immunosuppressed patients. There are no commercially available alternative antimicrobials, and multi-drug resistance is an urgent concern that requires emergency measures and new therapeutic strategies. This study evaluated a multi-drug-resistant A. baumannii whole-cell vaccine, inactivated and adsorbed on an aluminum hydroxide-chitosan (mAhC) matrix, in an A. baumannii sepsis model in immunosuppressed mice by cyclophosphamide (CY). CY-treated mice were divided into immunized, non-immunized, and adjuvant-inoculated groups. Three vaccine doses were given at 0D, 14D, and 28D, followed by a lethal dose of 4.0 × 10 8 CFU/mL of A. baumannii . Immunized CY-treated mice underwent a significant humoral response, with the highest IgG levels and a higher survival rate (85%); this differed from the non-immunized CY-treated mice, none of whom survived ( p < 0.001), and from the adjuvant group, with 45% survival ( p < 0.05). Histological data revealed the evident expansion of white spleen pulp from immunized CY-treated mice, whereas, in non-immunized and adjuvanted CY-treated mice, there was more significant organ tissue damage. Our results confirmed the proof-of-concept of the immune response and vaccine protection in a sepsis model in CY-treated mice, contributing to the advancement of new alternatives for protection against A. baumannii infections. |
